Ritedose Doubles Packaging Capacity with Seventh Syntegon Line

• Ritedose is installing a seventh Syntegon packaging line to double its capacity for individually wrapped vial medications.

• The new system will support products like Verona Pharma’s Ohtuvayre and process up to 170 million vials annually.

The Ritedose Corporation, Inc. has announced the installation of a seventh Syntegon packaging line at its advanced manufacturing facility, a move that will double its capacity for individually wrapped vial medications. The new line is expected to be operational by early summer 2025.

The company, a major CDMO in the United States specialising in sterile Blow-Fill-Seal (BFS) production, will now be able to process between 160 million and 170 million vials annually. This expansion is in response to growing market demand and will enhance Ritedose’s flexibility in serving ophthalmic and respiratory therapy providers.

The new packaging system will also support Ritedose’s role as the manufacturing partner for Verona Pharma plc’s Ohtuvayre, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). Ohtuvayre is noted as the first inhaled product with a new mechanism of action to receive approval in over 20 years.

“For more than 20 years, Ritedose has relied on Syntegon Technology… to deliver reliable, innovative solutions,” said Jody Chastain, President and Chief Executive Officer of Ritedose. “Our seventh Syntegon packaging line will greatly enhance our ability to serve Verona Pharma and future clients.”

The new system is currently undergoing Site Acceptance Testing. Designed specifically for automated secondary packaging of pharmaceutical and consumer goods, the Syntegon line is built to maximise output while minimising waste, reinforcing Ritedose’s focus on patient safety and high-quality contract manufacturing.